Allergic Conjunctivitis - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 70
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AB9137ABF19EN
Leaflet:

Download PDF Leaflet

Allergic Conjunctivitis - Pipeline Review, H2 2017
Allergic Conjunctivitis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2017, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 8 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Allergic Conjunctivitis - Overview
Allergic Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Allergic Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Allergic Conjunctivitis - Companies Involved in Therapeutics Development
Accolade Pharmaceuticals LLC
Aldeyra Therapeutics Inc
AlleCures Inc
Allergan Plc
Clevexel Pharma SAS
Griffin Discoveries BV
Ocular Therapeutix Inc
Ohr Pharmaceutical Inc
Portola Pharmaceuticals Inc
Re-Pharm Ltd
Realm Therapeutics Plc
Sylentis SAU
Xencor Inc
Allergic Conjunctivitis - Drug Profiles
ADX-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGN-229666 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPC-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Allergic Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GD-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GD-136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYL-116011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-7195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zafi-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergic Conjunctivitis - Dormant Projects
Allergic Conjunctivitis - Discontinued Products
Allergic Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Oct 16, 2017: Realm Therapeutics to Present Update on Drug Development Program PR013 at 2017 BIO Investor Forum
Oct 10, 2017: Aldeyra Therapeutics Announces New Data on ADX-102 at 2017 Research & Development Day
Sep 27, 2017: Aldeyra Therapeutics Announces 2017 Research and Development Day
Sep 21, 2017: Realm Therapeutics Provides Clinical Development Update on PR013
Sep 11, 2017: Realm Therapeutics - FDA Permits PR013 to Proceed to Phase II Trial
Sep 07, 2017: Realm Therapeutics to present update on PR013 at the Rodman & Renshaw 19th Annual Global Investment Conference
Aug 02, 2017: Realm Therapeutics Submits Investigational New Drug Application for PR013 for Allergic Conjunctivitis
Jul 06, 2017: Realm Therapeutics - Presentation at World Congress on Inflammation
Jun 14, 2017: Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
Jun 14, 2017: Realm Therapeutics to present on PR013 at the 2017 Marcum Microcap Conference
Jun 13, 2017: Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial
Apr 18, 2017: Aldeyra Therapeutics Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
Feb 07, 2017: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial
Jan 05, 2017: Realm Therapeutics to provide update on PR013 at the 2017 Dermatology Summit and Biotech Showcase
Dec 05, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Allergic Conjunctivitis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals LLC, H2 2017
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H2 2017
Allergic Conjunctivitis - Pipeline by AlleCures Inc, H2 2017
Allergic Conjunctivitis - Pipeline by Allergan Plc, H2 2017
Allergic Conjunctivitis - Pipeline by Clevexel Pharma SAS, H2 2017
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2017
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, H2 2017
Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc, H2 2017
Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals Inc, H2 2017
Allergic Conjunctivitis - Pipeline by Re-Pharm Ltd, H2 2017
Allergic Conjunctivitis - Pipeline by Realm Therapeutics Plc, H2 2017
Allergic Conjunctivitis - Pipeline by Sylentis SAU, H2 2017
Allergic Conjunctivitis - Pipeline by Xencor Inc, H2 2017
Allergic Conjunctivitis - Dormant Projects, H2 2017
Allergic Conjunctivitis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Allergic Conjunctivitis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Allergic Conjunctivitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Accolade Pharmaceuticals LLC
Aldeyra Therapeutics Inc
AlleCures Inc
Allergan Plc
Clevexel Pharma SAS
Griffin Discoveries BV
Ocular Therapeutix Inc
Ohr Pharmaceutical Inc
Portola Pharmaceuticals Inc
Re-Pharm Ltd
Realm Therapeutics Plc
Sylentis SAU
Xencor Inc
Skip to top


Ask Your Question

Allergic Conjunctivitis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: